Triferic Avnu is a drug owned by Rockwell Medical Inc. It is protected by 1 US drug patent filed in 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 17, 2029. Details of Triferic Avnu's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US7816404 | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
Apr, 2029
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Triferic Avnu's patents.
Latest Legal Activities on Triferic Avnu's Patents
Given below is the list of recent legal activities going on the following patents of Triferic Avnu.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 22 Mar, 2022 | US7816404 |
| Email Notification Critical | 16 Jan, 2019 | US7816404 |
| Correspondence Address Change Critical | 15 Jan, 2019 | US7816404 |
| Change in Power of Attorney (May Include Associate POA) Critical | 15 Jan, 2019 | US7816404 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Apr, 2018 | US7816404 |
| Change in Power of Attorney (May Include Associate POA) Critical | 17 Jan, 2014 | US7816404 |
| Correspondence Address Change Critical | 16 Jan, 2014 | US7816404 |
| Post Issue Communication - Certificate of Correction | 24 Feb, 2011 | US7816404 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Oct, 2010 | US7816404 |
| Recordation of Patent Grant Mailed Critical | 19 Oct, 2010 | US7816404 |
US patents provide insights into the exclusivity only within the United States, but Triferic Avnu is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Triferic Avnu's family patents as well as insights into ongoing legal events on those patents.
Triferic Avnu's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Triferic Avnu's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 17, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Triferic Avnu Generics:
There are no approved generic versions for Triferic Avnu as of now.
Alternative Brands for Triferic Avnu
Triferic Avnu which is used for treating patients with iron deficiency and in need of iron replacement therapy., has several other brand drugs using the same active ingredient (Ferric Pyrophosphate Citrate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Rockwell Medical Inc |
|
About Triferic Avnu
Triferic Avnu is a drug owned by Rockwell Medical Inc. It is used for treating patients with iron deficiency and in need of iron replacement therapy. Triferic Avnu uses Ferric Pyrophosphate Citrate as an active ingredient. Triferic Avnu was launched by Rockwell Medical Inc in 2020.
Approval Date:
Triferic Avnu was approved by FDA for market use on 27 March, 2020.
Active Ingredient:
Triferic Avnu uses Ferric Pyrophosphate Citrate as the active ingredient. Check out other Drugs and Companies using Ferric Pyrophosphate Citrate ingredient
Treatment:
Triferic Avnu is used for treating patients with iron deficiency and in need of iron replacement therapy.
Dosage:
Triferic Avnu is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 6.75MG IRON/4.5ML (1.5MG IRON/ML) | SOLUTION | Discontinued | INTRAVENOUS |